Literature DB >> 19628164

Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C.

Geoffrey Dusheiko1.   

Abstract

Thrombocytopenia is a condition of unusually low level of platelets in blood, resulting from an imbalance between the production and destruction of platelets, and is associated with aplastic anemia, myelodysplasia, and idiopathic thrombocytopenic purpura (ITP). Thrombocytopenia can also be associated with severe chronic liver disease as a result of several factors that may act in concert, including reduced production of the endogenous thrombopoietic growth factor, thrombopoietin (TPO). This article examines the nature of thrombocytopenia, ITP, and TPO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628164     DOI: 10.1016/j.cld.2009.05.012

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  6 in total

1.  The current status of thrombopoietins in the management of liver disease.

Authors:  Hans L Tillmann
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-11

2.  Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly.

Authors:  Yunfu Lv; Wan Yee Lau; Hongfei Wu; XiaoYu Han; Xiaoguang Gong; Ning Liu; Jie Yue; Qingqing Li; YeJuan Li; Jie Deng
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

3.  Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience.

Authors:  D Kozielewicz; D Dybowska; W Halota; W Dróżdż
Journal:  Infection       Date:  2011-07-08       Impact factor: 3.553

4.  Hypersplenism: History and current status.

Authors:  Yunfu Lv; Wan Yee Lau; Yejuan Li; Jie Deng; Xiaoyu Han; Xiaoguang Gong; Ning Liu; Hongfei Wu
Journal:  Exp Ther Med       Date:  2016-09-07       Impact factor: 2.447

Review 5.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

6.  High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.

Authors:  Manuela Currao; Carlo L Balduini; Alessandra Balduini
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.